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Background: The concern for adverse events following immunization (AEFI) and anti-
vaccination movements that lacked scientific evidence-based supports may reduce 
vaccine uptake in the general population. Thus, the aims of the present study were 
to characterize AEFI in general population (all age groups), in terms of frequency, 
preventability, and seriousness and to define predictors of their seriousness in children.
Methods: A retrospective study was performed on suspected AEFI reports for children 
and adults who received any form of vaccinations, collected in Tuscany, Italy, between 
1 January and 31 December 2017. Patients’ characteristics, suspected vaccines, and 
AEFI description were collected. Causality and preventability were assessed using 
WHO and Schumock and Thornton algorithms, respectively. Logistic regression was 
used to estimate the reporting odds ratios of potential predictors of AEFI seriousness 
in children.
Results: A total of 223 suspected AEFI reports were collected, and the majority of 
them were defined as non-serious (76.7%). Reports were mostly related to one vaccine, 
and to a median of two to five strains/toxoids. The total number of simultaneously 
administered strains/toxoids and the presence of allergens did not correlate with AEFI 
seriousness. Considering vaccines with a high number of administered doses (≥60,000 
doses), the rates estimated for serious AEFI reports were always very low, ranging 
between 0.01 and 0.2/1,000 doses. Twenty-four vaccines (8,993 doses) were not 
related to any AEFI.
Conclusion: Results of present study showed that AEFI were very rare; the vast majority 
of them was non-serious and, despite the claims of anti-vaccination movements, the 
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simultaneous administration of vaccines was safe and did not influence the risk of 
reporting a serious AEFI, particularly in children.
Keywords: vaccines, adverse events following immunization, pharmacovigilance, safety, observational study, 
preventability, seriousness
INTRODUCTION
As vaccine-preventable infectious diseases continue to decline; 
parents and individuals in general have become increasingly 
concerned about the risks associated with vaccination. 
An adverse event following immunization (AEFI) is any 
untoward clinical occurrence which follows vaccinations and 
which does not necessarily have a causal relationship with 
vaccine use (Fulton et al., 2015; WHO, 2019a). An AEFI may 
be any unfavorable or unintended sign, abnormal laboratory 
finding, symptom, or disease. Moreover, AEFI classification 
may include: 1) vaccine product–related reaction (an AEFI 
that is caused or precipitated by a vaccine due to one or more 
of the inherent properties of the vaccine product), 2) vaccine 
quality defect–related reaction (an AEFI that is caused or 
precipitated by a vaccine that is due to one or more quality 
defects of the vaccine product including its administration 
device as provided by the manufacturer), 3) immunization-
related errors, 4) immunization anxiety–related reactions, 
and 5) coincidental events (Fulton et al., 2015; WHO, 2019a). 
AEFI can be also represented by minor events, manifesting 
as local (i.e., erythema, edema, pain) or systemic (i.e., fever, 
exanthema, allergic reactions), and severe events manifesting 
as anaphylaxis, seizures, thrombocytopenia, hypotonic hypo-
responsive episodes (HHE), or prolonged crying. Finally, an 
AEFI can be acute if it occurs within minutes after vaccine 
administration or delayed if it occurs several hours or days 
after vaccine administration (Danova et al., 2017). Considering 
the World Health Organization (WHO) criteria (WHO, 
2019b), several considerations for assessing causality of an 
AEFI should be always evaluated: 1) temporal relationship, 
2) alternative explanations, 3) proof of association, 4) prior 
evidence, 5) population-based evidence, and 6) biological 
plausibility. AEFI might be also related to strains/toxoids 
and/or to other vaccine components, such as: antibiotics (i.e., 
neomycin), components of the container (i.e., latex), residual 
proteins of the substrate (i.e., egg), or stabilizers (i.e., gelatine) 
(Autret-Leca et al., 2006).
In Italy, 18–25 AEFI reports are recorded every 100,000 
vaccine doses. Overall, on a total of 4,766 AEFI reports collected 
during 2016 at the National level, more than 80% were defined 
as non-serious (AIFA, 2018). Nevertheless, in the last decade, 
public health authorities worldwide have observed an increase 
in the number of vaccine hesitant patients or parents (Larson 
et al., 2016) and an increase in “anti-vaccination” movements 
activities (Tafuri et al., 2015). The concern for vaccine safety 
and dearth of studies documenting surveillance of their adverse 
effects were the major theme of anti-vaccination movements 
(Tafuri et al., 2015). As a consequence, immunization coverage 
in Italy has decreased both in children (Signorelli et al., 2017) 
and adults (Pezzotti et al., 2018) in recent years. Compulsory 
vaccination for children, therefore, became enacted into Law 
in July 2017 (Law n. 119) in order to address the vaccination 
short fall in Italy. Consequently, the number and uptake of 
compulsory vaccination have increased from 4 to 10 (Scavone 
et al., 2018b). These are those included in the hexavalent 
vaccine (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis 
B, and hemophilus influenzae B) and measles, mumps, rubella, 
and varicella, for children up to 6 years of age to be enrolled 
in kindergartens and pre-schools and for children up to 16 
years of age to attend compulsory schools. Furthermore, health 
authorities are requested to promote all vaccines (mandatory 
and non-mandatory) recommended in the 2017–2019 National 
Immunisation Plan (Scavone et al., 2018b). As a matter of 
fact, vaccines such as those against Neisseria meningitidis, 
Streptococcus pneumoniae, or human papilloma virus are not 
included in the mandatory vaccination law; however, they 
are included in the recent Italian National Vaccination Plan 
(2015–2017) and are given free of charge to all newborns 
(Neisseria meningitidis and Streptococcus pneumoniae) or to all 
adolescents, both male and female (HPV vaccine).
Thus, improving AEFI characterization in the general and 
pediatric population remains a public health and a patient 
safety perception priority, especially after the new regulatory 
decision. Moreover, to the best of our knowledge, no studies have 
been previously conducted to assess the possible association 
between vaccines’ characteristics (number of strains/toxoids 
simultaneously administered and presence of allergens as 
reported in the summary of product characteristic, SPC) and 
AEFI reporting.
The aim of the present study was to characterize AEFI in the 
general population evaluating their frequency in relation to the total 
number of administered doses, their preventability, and seriousness. 
Moreover, we also identified predictors of AEFI seriousness in 
children, by means of 1-year pharmacovigilance study.
MATERIAL AND METHODS
This is a retrospective study performed on reports of suspected 
AEFI collected in Tuscany, Italy, between 1 January and 31 
December, 2017, and related only to vaccinations performed 
during such period. We analyzed all suspected AEFI reported 
from patients having at least one AEFI. All AEFI reports were 
collected through both the regional spontaneous reporting system 
and two active pharmacovigilance projects, Monitoring of the 
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Adverse Effects in Pediatric population (MEAP) (Carnovale et al., 
2014) and Epidemiological Monitoring of Adverse Drug Reactions 
in Emergency Department (MEREAFaPS) (Lombardi et al., 2018).
Each AEFI report demographic characteristics, including age, 
sex, and ethnic group, were recorded. Anatomical Therapeutic 
Chemical (ATC) classification system was used to code both 
vaccine administered and concomitant medications, for which 
we also recorded the administration route, therapy duration, 
and dosage. The description of AEFI according to diagnosis 
and symptoms was coded using the Medical Dictionary for 
Regulatory Activities (MedDRA) and organized by System 
Organ Class (SOC) (Lombardi et al., 2018). Seriousness of 
AEFI was classified according to the World Health Organization 
(WHO) criteria (Lombardi et al., 2018) as fatal, life-threatening, 
requiring hospitalization of the patient, or causing serious/
permanent disability.
The most frequently reported SOC and ATC classes were 
also evaluated. For each AEFI report, causality (categorized 
as consistent, inconsistent, indeterminate, or unclassifiable) and 
preventability (categorized as definitely or probably preventable, or 
not preventable) were assessed using the WHO algorithm (Tozzi 
et al., 2013; WHO, 2018) and Schumock and Thornton algorithm 
(Schumock and Thornton, 1992), respectively. Both assessments 
were performed by a multidisciplinary team composed by 
experts in clinical pharmacology, immunology, epidemiology, 
and pediatrics. The same team revised data on concomitant 
medications and analyzed vaccine–vaccine (VVI), vaccine-
drug (VDI), and drug–drug (DDI) interactions using the drug 
interaction software Micromedex Drug-REAX System (Thomson 
Reuters Healthcare Inc., Greenwood Village, Colorado, United 
States), available online with restricted access (Santos et al., 
2017). As reported in the Micromedex tool (Micromedex® 2.0, 
2013), interactions were classified as mild, moderate, or severe, 
depending on their clinical complexity.
For each vaccine, the number of bacterial or viral strains and 
toxoids was obtained from the specifications listed in the SPC. In 
case of multiple vaccines’ administration in the same vaccination 
session, we obtained the total amount of strains/toxoids 
administered by summing the number of strains/toxoids for each 
product. Allergens listed in the SPC were considered together as 
a dichotomous variable (presence/absence). We considered the 
presence/absence of: neomycin and/or other antibiotics in traces, 
latex, egg, gelatine, etc.
For the general population (all age groups), the frequency 
of total and serious AEFI was calculated in relation to the total 
number of vaccines doses administered in Tuscany, Italy, in 
2017. AEFI rates were calculated dividing the number of AEFI 
reports by the total number of administered doses for each ATC 
of interest and expressed as AEFI reports/administered doses x 
1,000. Data regarding AEFI reports and vaccines administered 
doses were obtained by the Regional Health Authority, after 
having been made anonymous. Due to the lack of information on 
total administered doses for influenza vaccines, all ATC classes 
related to these products were not included in the analysis, and 
AEFI rates for them were not calculated. AEFI reports potentially 
associated with those vaccines were nevertheless collected, 
assessed, and discussed.
For subjects ≤18 years, predictors of AEFI seriousness, such as 
age groups, sex, number of vaccines simultaneously administered, 
vaccines characteristics (number of strains/toxoids and presence 
of allergens), and interactions (DDIs, VDIs, VVIs), were also 
evaluated. For children, age groups were codified using Food and 
Drug Administration (FDA) classification (FDA, 2014).
Descriptive statistics were used to summarize data. 
Categorical data were reported as frequencies and percentages 
and compared using the chi-square or Fischer exact tests, as 
appropriate, whereas continuous data were reported as median 
values with the related interquartile ranges (IQR) and compared 
using the Mann-Whitney test. Univariate and multivariate 
logistic regressions were used to estimate the reporting odds 
ratios (RORs) with 95% confidence intervals (CIs) of potential 
predictors of AEFI seriousness in children. ROR values for 
each variable were reported both as crude and adjusted values 
and adjusted for all the other considered variables. All results 
were considered to be statistically significant at p < 0.05. 
Data management and statistical analysis were carried out 
using STATA 14.
The coordinating center of Tuscany, Italy, approved 
MEREAFaPS project (notification number 1225—December 21, 
2009), and the local institutional ethics committee approved 
MEREAFaPS (study number 3055/2010, protocol number 
45288—August 6, 2014) according to the legal requirements 
concerning observational studies. The MEAP project was 
approved in the frame of MEREAFaPS. Due to the retrospective 
nature of the present study and data anonymization, patient’s 
consent to participate was not required.
RESULTS
In 2017, the entire population of Tuscany included around 
3,736,968 inhabitants, of which 601,160 (16%) were children. 
Within the study period, a total of 223 AEFI reports were collected 
and evaluated; of them, 171 (76.7%) were defined as non-serious, 
and 52 (23.3%) were defined as serious. Table 1 shows the 
characteristics of all suspected AEFI reports (on the top of Table 1) 
and the characteristics of each AEFI (on the bottom of Table 1) in 
the general population.
Characteristics of AEFI Reports
The median age was 9.24 years (IQR, 1.14–42.17), and children 
(n = 142, 63.7%) experienced more AEFI than adults. However, 
there was no statistically significant difference among age groups 
when serious and non-serious AEFI reports were compared 
(p = 0.664). We encountered more AEFI reports referred to males 
than females, and the distribution of the type of events according 
to sex was significantly different (p = 0.036). AEFI reports were 
more common among Caucasians.
Evaluating the causality assessment, 153 AEFI reports (68.6%) 
were defined as consistent with the vaccination, 24 (10.8%) as 
inconsistent, 44 (19.7%) as indeterminate, and 2 (0.9%) were 
defined as unclassifiable. Applying the Schumock and Thornton 
algorithm, more than 90% of suspected AEFI reports were classified 
as non-preventable, while 16 reports were defined as preventable.
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TABLE 1 | Characteristics of all AEFI reports (top) and each AEFI (bottom) in general population.
Tot reports
n = 223 (%)
Non-serious
n = 171 (%)
Serious
n = 52 (%)
p-Value
N AEFI for each report
1 76 (34.08) 57 (33.33) 19 (36.54) 0.503
2 43 (19.28) 35 (20.47) 8 (15.38)
3 49 (21.97) 40 (23.39) 9 (17.31)
4+ 55 (24.66) 39 (22.81) 16 (30.77)
Age, years (overall)
Median (IQR) 9.24 (1.14–42.17) 9.95 (1.24–44.25) 2.26 (0.84–22.28) 0.091
Pediatric age groups (FDA classification)
Newborns (< 1 month) 0 0 0 0.664
Infants (1 month–2 years) 57 (25.56) 40 (23.39) 17 (32.69)
Children (2–12 years) 73 (32.74) 56 (32.75) 17 (32.69)
Adolescents (12–18 years) 12 (5.38) 8 (4.68) 4 (7.69)
Adults (quartiles of age)
19–39 years 20 (8.97) 16 (9.36) 4 (7.69)
40–49 years 21 (9.42) 18 (10.53) 3 (5.77)
50–59 years 15 (6.73) 13 (7.60) 2 (3.85)
Over 60 years 25 (11.21) 20 (11.70) 5 (9.62)
Sex
Female 102 (45.74) 84 (49.12) 18 (34.62) 0.036
Male 114 (51.12) 80 (46.78) 34 (65.38)
Missing 7 (3.14) 7 (4.09) 0
Ethnic group
Caucasian 137 (61.43) 106 (61.99) 31 (59.62) 0.880
Others 14 (6.28) 10 (5.85) 4 (7.69)
Missing 72 (32.29) 55 (32.16) 17 (32.69)
Causality
Consistent 153 (68.61) 129 (75.44) 24 (46.15)  <0.001
Inconsistent 24 (10.76) 7 (4.09) 17 (32.69)
Indeterminate 44 (19.73) 33 (19.30) 11 (21.15)
Unclassifiable 2 (0.90) 2 (1.17) 0
Preventability
No 207 (92.80) 162 (94.74) 45 (86.53) 0.016
Yes 16 (7.20) 9 (5.26) 7 (13.47)
Tot AEFI
n = 570
Non-serious
n = 431
Serious
n = 139
p-Value
Number of suspect drug for each AEFI
1 489 (85.79) 379 (87.94) 110 (79.14) 0.002
2 74 (12.98) 45 (10.44) 29 (20.86)
3 7 (1.23) 7 (1.62) 0
Concomitant drugs (not suspected)
0 502 (88.07) 383 (88.86) 119 (85.61) 0.023
1 35 (6.14) 22 (5.10) 13 (9.35)
2 23 (4.04) 21 (4.87) 2 (1.44)
3 9 (1.58) 5 (1.16) 4 (2.88)
4 1 (0.18) 0 1 (0.72)
Tot strains/toxoids
Median (IQR) 4 (4-7) 4 (3-7) 4 (4-6) 0.815
1 51 (8.95) 36 (8.35) 15 (10.79) 0.940
2–5 364 (63.86) 277 (64.27) 87 (62.59)
6–9 53 (9.30) 40 (9.28) 13 (9.35)
10–13 26 (4.56) 20 (4.64) 6 (4.32)
14+ 76 (13.33) 58 (13.46) 18 (12.95)
Presence of allergens (in traces) 
Yes 222 (38.95) 180 (41.76) 42 (30.22) 0.015
No 348 (61.05) 251 (58.24) 97 (69.78)
Seriousness (out of 139)
Death 0 - 0 -
Persistent or significant disability/incapacity 8 (5.76) - 8 (5.76)
Congenital abnormalities/birth defects 0 - 0
Hospitalization or prolongation 83 (59.71) - 83 (59.71)
Life-threatening condition 0 - 0
Other clinically relevant conditions 48 (34.53) - 48 (34.53)
(Continued)
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In particular, within preventable AEFI reports, we encountered: 
six cases of major VDIs observed between Pneumococcus, 
purified polysaccharides antigen-conjugated (ATC J07AL02), and 
acetaminophen; one case of moderate VDI observed between 
varicella, live-attenuated (ATC J07BK01), and betamethasone; 
one case of moderate VVI observed between Meningococcus C, 
purified polysaccharides antigen-conjugated (ATC J07AH07), and 
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-
hepatitis B (ATC J07CA09); three cases of post-immunization 
hypersensitivity reactions in patients with a previous history of 
allergy; three cases of patients who developed the same AEFI 
experienced following the administration of previous doses for 
the same vaccine (positive rechallenge); one case of therapeutic 
error; and one case of AEFI report observed following live-
attenuated rotavirus (ATC J07BH01) administration in a patient 
with a previous history of intestinal intussusception.
Characteristics of AEFI
Regarding each AEFI (n = 570), the majority of them was 
associated with only 1 vaccine (n = 489, 85.8%), and 139 (24.4%) 
were defined as “serious.” Of the 139 serious AEFI reported in 
this study, 83 (59.7%) resulted in hospitalization, and 48 were 
represented by “other clinically relevant conditions” (i.e., all 
adverse events judged by the reporter as clinically relevant 
because they required an intervention to prevent one of the 
other characteristics and consequences related to death, or life 
threatening, or hospitalization, or permanent disability, etc.). 
“Hospitalization or prolongation” group was mostly associated 
with vaccine-related fever, and within “other clinically relevant 
conditions” group; only two cases of death (for a total of five 
vaccine-AEFI pairs) were observed.
These fatal cases involved two women, aged 68 and 97 
years old (data not shown in Table 1), who died for an acute 
respiratory tract infection (suspected vaccine ATC J07AL02) 
and for a cardiac failure in hypertensive cardiopathy (suspected 
vaccine ATC J07BB02), respectively. After an accurate clinical 
evaluation, these fatal cases were judged as not associated to 
vaccination. Finally, we encountered eight vaccine-AEFI pairs 
(derived from two AEFI reports) associated to “persistent or 
significant disability/incapacity” group, which were reported 
by patient/citizen and, consequently, misclassified. In fact, the 
clinical evaluation performed by the panel of experts revealed 
that these AEFI had indeed a complete resolution and were not 
causally consistent with vaccination.
Regarding the outcome, 366 (64.2%) AEFI were completely 
resolved or improved, and 78 (13.7%) were still unresolved at the 
time of reporting. The outcome was missing for 114 (20%) AEFI. 
Finally, the outcome of five (0.9%) AEFI was defined as resolution 
with sequelae and referred to a single patient for whom the observed 
events were not associated to the vaccination. Of note, as mentioned 
above, for a total of five vaccine-AEFI pairs (0.9%) classified within 
the “other clinically relevant conditions” group and associated with 
the outcome death, the clinical evaluation revealed that these events 
were not causally correlated with vaccination.
Out of a total of 120 AEFI, only 14 of them presented a 
moderate (n = 2) or severe (n = 12) interaction. These interaction-
related AEFI derived from eight AEFI reports (seven cases 
of VDIs, one case of VVI) described above in the section of 
reports’ characteristics.
Following MedDRA hierarchy, 267 (46.8%) out of 570 
AEFI belonged to “general disorders and administration site 
conditions,” 67 (11.7%) involved “nervous system disorders,” 
62 (10.9%) involved “skin and subcutaneous tissue disorders,” 
60 (10.5%) involved “gastrointestinal disorders,” and 30 
(5.3%) involved “musculoskeletal disorders.” Consequently, 
the five most frequently reported preferred terms were: fever 
(17.5%), pain at site of vaccination (5.3%), rash at site of 
vaccination (5.3%), rash at unspecified site (5.1%), and edema 
at site of vaccination (4.7%) (Supplementary Table 1). Of note, 
within the SOC “nervous system disorders,” only six cases 
of febrile-related seizures were reported, all of them with a 
complete resolution.
TABLE 1 | Continued
Tot reports
n = 223 (%)
Non-serious
n = 171 (%)
Serious
n = 52 (%)
p-Value
Outcome
Complete resolution 247 (43.33) 184 (42.69) 63 (45.32)  <0.001
Improvement 119 (20.88) 98 (22.74) 21 (15.11)
Still unresolved# 78 (13.68) 50 (11.60) 28 (20.14)
Resolution with sequelae 5 (0.88) 5 (1.16) 0
Unchanged/worsened reaction 2 (0.35) 2 (0.46) 0
Death 5 (0.88) 0 5 (3.60)
Missing° 114 (20.00) 92 (21.35) 22 (15.83)
Interactions (DDIs + VDIs + VVIs)
Not applicable (one treatment) 450 (78.95) 346 (80.28) 104 (74.82) 0.032
No 106 (18.60) 78 (18.10) 28 (20.14)
Mild 0 0 0
Moderate 2 (0.35) 2 (0.46) 0
Severe 12 (2.11) 5 (1.16) 7 (5.04)
IQR, interquartile range; FDA, Food and Drug Administration; DDI, drug–drug interaction; VDI, vaccine-drug interaction; VVI, vaccine–vaccine interaction.
#From a case-by-case evaluation these events were classified as still unresolved due to the fact that the AEFI reporting was performed immediately after AEFI onset.
°These events were classified as missing because the reporter did not complete the relative section present in the AEFI reporting form.
p-value was from Fisher Exact test for percentages and Mann-Whitney test for median values.
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Supplementary Table 2 shows the characteristics of all 
suspected AEFI reports (on the top) and the characteristics of 
each AEFI (on the bottom) observed for pediatric population, 
described taking into consideration the current National 
Vaccination Plan 2017–2019. As already reported for the 
general population, we observed similar results also for the 
pediatric one.
Administered Doses and AEFI Reporting
Considering all vaccines doses administered in Tuscany, we 
observed very few AEFI reports for vaccines with a high 
frequency of usage (more than 60,000 doses). In particular, as 
reported in Table 2, the most frequently administered vaccines 
were: Meningococcus B, multicomponent vaccine (117,525 doses); 
Meningococcus C, purified polysaccharides antigen-conjugated 
(109,515 doses); Pneumococcus, purified polysaccharides antigen-
conjugated (72,273 doses); diphtheria-hemophilus influenzae 
B-pertussis-poliomyelitis-tetanus-hepatitis B (65,158 doses); 
and Meningococcus A, C, Y, and W-135, tetravalent purified 
polysaccharides antigen-conjugated (61,590 doses). For them, the 
rates of total and serious AEFI reports per 1,000 administered 
doses were very low and varied from 0.07 to 0.54, and from 
0.01 to 0.20, respectively. Several vaccines were not associated 
with any AEFI. Supplementary Table 3 reports the number of 
administered doses of all ATC classes for which no AEFI reports 
were collected during the study period.
Predictors of AEFI Seriousness in Children
Table 3 shows demographic and clinical features associated 
with the risk of serious AEFI reporting in the pediatric age 
classes specifically mentioned in the National Vaccination 
Plan 2017–2019. Male sex and the presence of concomitant 
(not suspected) drugs were associated with a significantly 
higher risk of AEFI reported as serious. The total amount of 
strains/toxoids administered and the presence of allergens 
were not associated with AEFI seriousness, for all evaluated 
age groups.
Distribution of AEFI Reports
Figure 1 describes the distribution of AEFI reports collected 
for mandatory (J07CA09, J07CA02, J07BK01, J07BD54, J07BD52) 
and non-mandatory (J07BH01, J07AL02, J07AH09, J07AH07) 
vaccinations performed between 0 and 15 months of age, 
according to the National Vaccination Plan 2017–2019. For 
other vaccinations (mandatory and non-mandatory), no 
AEFI reports were collected in children aged 0–15 months. 
Dashed areas represents the age period when vaccination 
should be administered. The majority of AEFI reports (non-
serious and serious) occurred within the time window for 
vaccine administration, demonstrating that vaccinations, were 
administered strictly following health authority dispositions. 
Some non-serious AEFI occurred before or after the 
recommended time window for vaccination, in particular to those 
related to Meningococcus B, multicomponent vaccine (J07AH09), 
and diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-
tetanus-hepatitis B (J07CA09). Data related to the other age groups 
are shown in the Supplementary Table 4.
DISCUSSION
This study aimed to characterize AEFI in the general population, 
evaluating their frequency in relation to the total number of 
administered doses and their preventability and seriousness, and 
to identify predictors of AEFI seriousness in children. To the 
best of our knowledge, this is the first study considering vaccine 
characteristics, in particular to the number of strains/toxoids 
simultaneously administered and the presence of allergens, as 
factors potentially associated to AEFI seriousness in patients 
aged ≤18 years. Moreover, our study was performed in the light 
of the last Italian National Vaccination Plan 2017–2019.
In terms of immunization safety, our study showed a higher 
frequency of non-serious AEFI reports, both in the general 
and in the pediatric population. Moreover, the majority of the 
events were not preventable, highlighting the appropriateness 
of vaccines use and administration in the observed population. 
In fact, the specific algorithm used to assess AEFI preventability 
contains a section which helps the assessor to evaluate whether 
or not an AEFI is related to an inappropriate use of the vaccine 
(Schumock and Thornton, 1992). In particular, the answer “NO” 
to the points 2 and 3 (Section A) of the algorithm indicates 
a high level of appropriateness of vaccination. Most of the 
preventable AEFI reports were due to the potential interaction 
between the components of the vaccines or between the vaccines 
and concomitant medications administered to the patients. 
Previous studies have documented poor immunologic response 
to conjugated Pneumococcus vaccine following acetaminophen 
administration (Prymula et al., 2009; Falup-Pecurariu et al., 2017; 
Wysocki et al., 2017). We also reported one case of interaction 
between varicella, live-attenuated vaccine, and the glucocorticoid 
betamethasone, which may result in an inadequate immunological 
response to the live vaccine (Infectious Diseases and Immunization 
Committee, Canadian Paediatric Society, 2000; Liu et al., 2013). 
Finally, we collected a VVI reported between Meningococcus 
C, purified polysaccharides antigen-conjugated vaccine, and 
diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-
tetanus-hepatitis B vaccine. The administration of Meningococcal 
groups A, C, and W-135 and Y conjugate vaccine after the Tetanus 
toxoid vaccine may result in lower geometric mean titers against 
groups A, C, and W-135 (Rivera et al., 2018). In particular, the 
present interaction was observed in a 2-year old female who 
received the two vaccinations out of the time window indicated for 
the administration of these vaccines, both in the SPC and in the 
National Vaccination Plan 2017–2019.
In our study, the most common AEFI related to vaccines were 
fever, injection-site reactions, rash, vomit, and fatigue, i.e., mild 
and transient untoward medical occurrences. Our results are 
comparable to those already published in literature, both in adults 
(Alguacil-Ramos et al., 2016; Mentzer et al., 2018) and in children 
(Danova et al., 2017; Lopes et al., 2018; Mentzer et al., 2018). We also 
reported six cases of febrile-related seizures (i.e., 1.05% of AEFI). 
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Although all of them were classified as serious, since they caused 
an emergency department (ED) admission, a complete resolution 
was reported in all cases. The majority of vaccines can cause 
fever, and some children who develop a fever can have a seizure. 
However, studies showed there is one case of fever-triggered seizure 
for every 3,000 to 4,000 children who receive a vaccine (Marin 
et al., 2010), and these seizures almost never cause harm over the 
long term (Committee to Review Adverse Effects of Vaccines, 
2011). Considering AEFI-related ED visits or hospitalizations, the 
majority of them were referred to the preferred terms “fever” and 
“hyperpyrexia,” adverse events well known and well characterized 
after vaccination (Sawyer et al., 2016).
Considering the high number of vaccine doses administered 
in Tuscany in 2017 (more than 600,000 doses), the total number 
of vaccine-related AEFI detected in the present study is low 
and provides a useful documentation of vaccination safety, 
both in adults and in children (Staltari et al., 2013). Notably, in 
terms of causality, no death was associated with vaccination. In 
fact, regarding the first case of decease, the suspected vaccine 
was ATC J07AL02 (Pneumococcus, purified polysaccharides 
antigen-conjugated), but clinical examination revealed that lung 
infection was attributable to a pneumococcal strain different 
from those contained in the 13-valent vaccine, excluding a 
vaccination failure. In the second case of death, suspected 
vaccine was ATC J07BB02 (influenza, inactivated, split virus, or 
surface antigen), which caused a fever-related ED visit, but the 
decease occurred 15 days later and was related to a pre-existent 
heart failure.
Concurrent administration of vaccines with multiple 
strain/toxoid was not a predictor of serious AEFI in this study. 
Findings from previous studies are in agreement with our report 
(Shinefield et al., 1998; Miller et al., 2011; Vesikari et al., 2013) 
showing that two or more vaccines could be administered safely 
during the same vaccination session. Administering a child with 
several vaccines during the same visit offers some advantages, 
both in terms of an earlier onset of protection and in terms of 
saving costs and time. Moreover, the administration of multiple 
vaccines can represent a valuable measure to reduce pain at time 
of vaccination (Saleh et al., 2017). Babies’ vaccination-related 
anxiety could be less significant when two or more vaccines are 
TABLE 2 | Number of administered doses and rates of AEFI reports in general population.
Vaccine ATC N strains/
toxoids
N AEFI 
report 
total
N AEFI 
report 
serious
N 
administered 
doses
Rate of total 
AEFI reports 
per 1,000 
doses
Rate of serious 
AEFI reports 
per 1,000 
doses
Meningococcus B, multicomponent vaccine J07AH09 4 63 23 117525 0.54 0.20
Meningococcus C, purified polysaccharides 
antigen-conjugated
J07AH07 2 8 1 109515 0.07 0.01
Pneumococcus, purified polysaccharides 
antigen-conjugated
J07AL02 14 30 8 72273 0.42 0.11
Diphtheria-hemophilus influenzae B-pertussis-
poliomyelitis-tetanus-hepatitis B
J07CA09 10 18 2 65158 0.28 0.03
Meningococcus A, C, Y, and W-135 tetravalent 
purified polysaccharides antigen-conjugated
J07AH08 5 27 2 61590 0.44 0.03
Pertussis, purified antigen, combinations with toxoids J07AJ52 5 9 2 55478 0.16 0.04
Measles, combinations with mumps, rubella and 
varicella, live-attenuated
J07BD54 4 14 4 45989 0.30 0.09
Diphtheria-pertussis-poliomyelitis-tetanus J07CA02 8 11 1 44188 0.25 0.02
Papillomavirus (human types 16, 18) J07BM02 4 4 0 21179 0.19 0.00
Measles, combinations with mumps and rubella, 
live-attenuated
J07BD52 3 23 8 18837 1.22 0.42
Tetanus toxoid, combinations with diphtheria toxoid J07AM51 2 4 0 13598 0.29 0.00
Varicella, live-attenuated J07BK01 1 4 1 13351 0.30 0.07
Tetanus toxoid J07AM01 1 9 2 12669 0.71 0.16
Hepatitis B, purified antigen J07BC01 1 6 1 8826 0.68 0.11
Hepatitis A, inactivated, whole virus J07BC02 1 1 0 8803 0.11 0.00
Rota virus, live-attenuated J07BH01 1
6 2 8499 0.71 0.24
Rota virus, pentavalent, live, reassorted J07BH02 5
Typhoid, oral, live-attenuated J07AP01 1 2 1 3045 0.66 0.33
Poliomyelitis oral, trivalent, live-attenuated J07BF02 3 1 0 2137 0.47 0.00
Poliomyelitis, trivalent, inactivated, whole virus J07BF03 3
Poliomyelitis oral, bivalent, live-attenuated J07BF04 2
Cholera, inactivated, whole cell J07AE01 5 1 1 1495 0.67 0.67
Papillomavirus (human types 6, 11, 16, 18, 31, 33, 
45, 52, 58)
J07BM03 9 1 1 793 1.26 1.26
Rabies, inactivated, whole virus J07BG01 1 1 0 439 2.28 0,00
Pneumococcus, purified polysaccharides antigen J07AL01 23 2 1 351 5.70 2.85
Diphtheria-hemophilus influenzae 
B-pertussis-poliomyelitis-tetanus
J07CA06 8 1 1 152 6.58 6.58
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administered once than in more than one vaccination sessions 
(Dodd, 2003). Reducing the number of sessions provides benefits 
not only to infants, but also to parents, healthcare providers, 
office managers, and managed care administrators.
In terms of AEFI, our results are comparable with those 
published in the scientific literature over the past decades, both 
in adults (Alguacil-Ramos et al., 2016; Mentzer et al., 2018) and 
in children (Danova et al., 2017; Lopes et al., 2018; Mentzer 
et al., 2018). The adverse events related to the use of vaccines 
occur at a very low frequency and are generally irrelevant when 
compared to risks associated to non-vaccination (Aps et al., 
2018). The overall literature provides no substantial indication 
of a causal relationship between immunization and the very 
occasional serious AEFI (Swedish Council on Health Technology 
Assessment, 2009). According to a 2014 study from the Centers 
for Disease Control and Prevention (CDC) (Whitney et al., 2014), 
TABLE 3 | Association between serious AEFI risk and different factors expressed as reporting odds ratio (ROR) within pediatric population stratified according to the age 
classes of the National Vaccination Plan 2017–2019.
0–15 months 16 months–12 years 12–18 years
Adjusted ROR 
(95% CI)
p-Value Adjusted ROR 
(95% CI)
p-Value Adjusted ROR 
(95% CI)
p-Value
Sex
Female Ref.
Male 1.26 (0.48–3.27) 0.639 2.29 (1.10–4.76) 0.027 0.20 (0.02–2.39) 0.203
Concomitant drugs 
(not suspected)
No Ref.
Yes 3.20 (0.96–10.70) 0.059 6.88 (1.42–33.43) 0.017 – –
Tot strains/toxoids
1–6 Ref.
6+ 0.16 (0.02–1.30) 0.087 2.14 (0.97–4.74) 0.060 – –
Presence of 
allergens (in traces) 
No Ref.
Yes 0.31 (0.04–2.56) 0.280 0.94 (0.45–1.98) 0.873 – –
FIGURE 1 | Distribution of AEFI reports (non-serious and serious) collected for mandatory and non-mandatory vaccinations performed between 0 and 15 months 
of age, according to the National Vaccination Plan 2017–2019 (dashed areas). Mandatory: “Diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-
hepatitis B” (J07CA09); “Diphtheria-pertussis-poliomyelitis-tetanus” (J07CA02); “varicella, live-attenuated” (J07BK01); “measles, combinations with mumps, 
rubella and varicella, live-attenuated” (J07BD54); “measles, combinations with mumps and rubella, live-attenuated” (J07BD52). Non-mandatory: “Rotavirus, 
live-attenuated” (J07BH01); “Pneumococcus, purified polysaccharides antigen-conjugated” (J07AL02); “Meningococcus B, multicomponent vaccine” (J07AH09); 
“Meningococcus C, purified polysaccharides antigen-conjugated” (J07AH07).
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vaccines have saved thousands of lives worldwide, in particular 
in children, preventing more than 300 million kids from getting 
sick only in United States. CDC also reported that the majority of 
AEFI (more than 90%) described in literature are generally not 
serious. A 2011 report from the National Academy of Medicine 
reviewed more than 1,000 vaccine studies and concluded that 
serious AEFI to vaccines are rare (Committee to Review Adverse 
Effects of Vaccines, 2011).
Another concern about vaccination safety refers to the 
presence of allergens, but as reported in our study, allergens could 
be considered safe and harmless (Matsumoto et al., 2017). To 
date, only few allergens in traces are currently present in human 
vaccines, and available evidences have already demonstrated their 
safety (Bastola et al., 2017). Data from the present study confirm 
that the presence of allergens in vaccines is not correlated with 
the onset of AEFI.
Focusing on Italy, the 2018 annual report on post-marketing 
surveillance of vaccines published by the Italian Medicines 
Agency (AIFA) showed a national rate of AEFI reporting of 11.1 
per 100,000 inhabitants for all vaccines (mandatory and non-
mandatory) (AIFA, 2018), while for Tuscany alone is of 8.0 per 
100,000 inhabitants. According to our data, the actual rate for 
Tuscany is even lower (5.95 per 100,000 inhabitants). In fact, 
in our analysis, only AEFI reports associated with vaccinations 
performed during 2017 were evaluated. Instead, AIFA annual 
report contains also AEFI reports referred to vaccination 
administered several years before 2017. The other variables 
considered by AIFA in the annual report (i.e., sex, age, SOCs, 
preferred terms, etc.) are consistent with our results.
STRENGTHS AND LIMITATIONS
This study has several limitations and strengths. First, its 
retrospective nature may have led to an underestimation of AEFI 
rate, since not all patients presenting an AEFI, even if serious, 
attend ED or spontaneously report the adverse event. However, 
considering that reporting all observed AEFI is compulsory for 
health professionals, and furthermore, data on AEFI reports in 
Tuscany were collected both through the regional spontaneous 
reporting system and two active pharmacovigilance projects, 
the issue of underreporting can be considered of relatively low 
relevance. Second, our analysis is based on AEFI reports that 
are affected by limits that include inaccurate and incomplete 
information, mainly related to lack of clinical data (Scavone et 
al., 2018a). Given that, we cannot always exclude the absence 
of information that was not listed in AEFI reports, and that 
might have influenced the clinical evaluation of each report 
(i.e., the lack of vaccination’s date or previous/current patient 
medical conditions which could affect the evaluation of causality 
assessment). Moreover, we have only Tuscan AEFI reports, which 
cannot be considered fully representative of the other Italian 
regions and, although our cases were all clinically evaluated, due 
to the large number of statistical tests performed the outcome 
of these tests should be regarded as descriptive. Given that the 
information on influenza vaccines administration is recorded 
in an administrative database different from those used for 
our analysis, we were not able to calculate the rate of AEFI to 
influenza vaccines in our sample.
Despite these limitations, this is the first retrospective analysis 
performed in Italy on potential predictors of AEFI seriousness in 
children over 1 year of observation. Moreover, focusing on AEFI 
reporting rate, since we evaluated AEFI related only to vaccination 
performed during 2017, our rate can be considered less influenced 
by the number of AEFI reports derived from the mass media 
influence on vaccination hesitancy observed in Italy before Law 
119/2017 (introducing mandatory vaccination for 10 vaccines) was 
approved. We strongly believe that pharmacovigilance studies are 
a valid scientific tool, simple and inexpensive, allowing healthcare 
professionals to detect and better characterize AEFI in clinical 
practice. In fact, we were able to highlight vaccination safety, showing 
a very low rate of AEFI and demonstrating that, particularly in 
children, their seriousness is not related to the number of vaccines 
and strains/toxoids simultaneously administered.
CONCLUSION
AEFI is a major concern, both regarding the public opinion as 
well as the healthcare politics, and it represents a challenge for 
healthcare professional and healthcare services. The present study 
provided new insights on the factors that might influence the risk 
of AEFI reporting in children (i.e., concomitant drugs, number 
of strains/toxoids simultaneously administered, and presence/
absence of allergens). Based on our results, the risks associated with 
immunization do not justify vaccination avoidance, especially 
because, among the risks related to vaccines, non-vaccination 
could be considered the most important. In this context, novel and 
specific educational approaches are needed in order to transmit the 
importance to correctly understand scientific research on vaccine 
safety to the younger generations of citizens, who will be the 
parents of tomorrow.
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